With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Construction at the Norton site is currently underway, with the new offerings anticipated to be operational by late 2027.

RNAi therapeutics company Alnylam Pharmaceuticals has announced the planned expansion of its manufacturing facility in Norton ...

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

Gov. Maura Healey is expected to be in Norton Wednesday morning to announce some good news: a $250 million expansion of a manufacturing plant run by Alnylam Pharmaceuticals, a publicly traded biotech ...

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were sinking 9.5% lower as of 11:27 a.m. ET on Thursday after falling as much as 12.6% earlier in the day. The sell-off came after the drugmaker ...

Analyst Ritu Baral of TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), retaining the price target of $282.00. Ritu Baral has given his Buy rating due to a combination of ...